Information de reference pour ce titreAccession Number: | 00000889-200311000-00030.
|
Author: | Van Staa, T. P. 1; Laan, R. F. 2; Barton, I. P. 3; Cohen, S. 4; Reid, D. M. 5; Cooper, C. 6
|
Institution: | (1)University of Southampton, Southampton, UK, Procter & Gamble Pharmaceuticals, Egham, UK, and Utrecht University, Utrecht, The Netherlands (2)University Medical Centre, Nijmegen, The Netherlands (3)Procter & Gamble Pharmaceuticals, Egham, UK (4)St. Paul Medical Center, Dallas, Texas (5)University of Aberdeen, Aberdeen, UK (6)University of Southampton, Southampton, UK.
|
Title: | |
Source: | Arthritis & Rheumatism. 48(11):3224-3229, November 2003.
|
Abstract: | Objective: To evaluate predictors of vertebral fractures, including a threshold for bone mineral density (BMD), in patients receiving oral glucocorticoids (GCs).
Methods: Data were obtained from 2 randomized clinical trials (prevention and treatment trials of risedronate) using similar methods, but different inclusion criteria were applied with regard to prior exposure to GCs. Predictors of vertebral fracture in the placebo group were identified using Cox regression with forward selection. The BMD threshold analysis involved a comparison of the 1-year fracture risk in postmenopausal women receiving placebo in the GC trials with that in postmenopausal women not taking GCs in 3 other trials.
Results: The study population comprised 306 patients with baseline and 1-year followup data on vertebral fractures (111 receiving placebo and 195 receiving risedronate). In the placebo group, the statistically significant predictors of incident fracture were the baseline lumbar spine BMD (for each 1-point decrease in T score, relative risk [RR] 1.85, 95% confidence interval [95% CI] 1.06-3.21) and the daily GC dose (for each 10-mg dose increase, RR 1.62, 95% CI 1.11-2.36). In the BMD threshold analysis, compared with nonusers of GCs, patients receiving GCs were younger, had a higher BMD at baseline, and had fewer prevalent fractures; nevertheless, the risk of fracture was higher in the GC users compared with nonusers (adjusted RR 5.67, 95% CI 2.57-12.54). The increased risk of fracture was observed in GC users regardless of whether osteoporosis was present.
Conclusion: The daily, but not cumulative, GC dose was found to be a strong predictor of vertebral fracture in patients receiving GCs. At similar levels of BMD, postmenopausal women taking GCs, as compared with nonusers of GCs, had considerably higher risks of fracture.
(C) 2003, American College of Rheumatology
|
References: | 1. Ettinger B, Pressman A, Shah HA. Who bears responsibility for glucocorticoid-exposed patients in a large health maintenance organisation. J Managed Care Pharm 2001;7:228-32.
2. Van Staa TP, Cooper C, Abenhaim L, Begaud B, Zhang B, Leufkens HGM. Utilisation of oral corticosteroids in the United Kingdom. Q J Med 2000;93:105-11.
3. Van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777-87.
4. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995;54:49-52.
5. Hooyman JR, Melton LJ, Nelson AM, O'Fallon M, Riggs BL. Fractures after rheumatoid arthritis. Arthritis Rheum 1984;27:1353-61.
6. Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000.
7. Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Fractures and oral corticosteroids: relationship to daily and cumulative dose. Rheumatol 2000;39:1383-9.
8. Walsh LJ, Wong CA, Oborne J, Cooper S, Lewis SA, Pringle M, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001;56:279-84.
9. Dykman TR, Gluck OS, Murphy WA, Hahn TJ, Hahn BH. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1985;28:361-8.
10. Manolagas SC. Corticosteroids and fractures: a close encounter of the third cell kind (editorial). J Bone Miner Res 2000;15:1001-5.
11. Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat JM, Setoain J. Vertebral fractures in steroid dependant asthma and involutional osteoporosis: a comparative study. Thorax 1991;46:803-6.
12. Selby PL, Halsey JP, Adams KRH, Klimiuk P, Knight SM, Pal B, et al. Corticosteroids do not alter the threshold for vertebral fracture. J Bone Miner Res 2000;15:952-6.
13. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, et al. Risedronate therapy prevents corticosteroid-induced bone loss. Arthritis Rheum 1999;42:2309-18.
14. Reid DM, Hughes RA, Laan RFJM, Sacco-Gibson NA, Wenderoth DH, Adami S, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroids-induced osteoporosis in men and women: a randomised trial. J Bone Miner Res 2000;15:1006-13.
15. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40.
16. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effect of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomised controlled trial. JAMA 1999;282:1344-52.
17. Reginster JY, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, et al. Randomized trials of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91.
18. Genant HK, Wu CY, Van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:1137-47.
19. SAS/GRAPH software: reference version 6. First ed. Vol. 1. Cary, NC:SAS Institute Inc.;1996.
20. Greenland S. Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 1995;6:356-65.
21. Naganathan V, Jones G, Nash P, Nicholson G, Eisman J, Sambrook PN. Vertebral fracture risk with long-term corticosteroid therapy. Arch Intern Med 2000;160:2917-22.
22. Peel NFA, Moore DJ, Barrington NA, Bax DE, Eastell R. Risk of vertebral fracture and relationship to bone mineral density in steroid treatment rheumatoid arthritis. Ann Rheum Dis 1995;54:801-6.
23. Johnell O, de Laet C, Johansson H, Melton LJ, Eisman J, Reeve J, et al. Oral corticosteroids increase fracture risk independently of BMD [abstract]. Osteoporos Int 2002;13 Suppl 1:S14.
24. Weinstein RS, Jilka RL, Parfitt M, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone. J Clin Invest 1998;102:274-82.
25. Weinstein RS, Powers CC, Parfitt AM, Manolagas SC. Preservation of osteocyte viability by bisphosphonates contributes to bone strength in glucocorticoid-treated mice independently of BMD: an unappreciated determinant of bone strength [abstract]. J Bone Miner Res 2002;17 Suppl 1:S156.
26. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2001;44:1496-503.
27. Bone and Tooth Society of Great Britain, Royal College of Physicians, and National Osteoporosis Society. Guidelines on the prevention and treatment of glucocorticoid-induced osteoporosis. London:Royal College of Physicians;2003.
28. Grados F, Roux C, de Vernejoul MC, Utard G, Sebert JL, Fardellone P. Comparison of four morphometric definitions and a semiquantitative concensus reading for assessing prevalent vertebral fractures. Osteoporos Int 2001;12:716-22.
|
Language: | English.
|
Document Type: | Research Article.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0004-3591
|
NLM Journal Code: | 0370605, 90m
|
Annotation(s) | |
|
|